| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $64,550,551 ) (Continued on the next page) |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255721 | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 | 000 | 5 | NIH | 11/13/2024 | $447,219 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286318 | Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1 | 000 | 2 | NIH | 1/8/2025 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 000 | 3 | NIH | 12/20/2024 | $432,117 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA248731 | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | 000 | 5 | NIH | 1/7/2025 | $353,720 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA285980 | Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs | 000 | 2 | NIH | 5/7/2025 | $530,632 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA267856 | Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi) | 000 | 4 | NIH | 12/18/2024 | $596,891 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 2 | NIH | 3/3/2025 | $605,071 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 001 | 3 | NIH | 3/12/2025 | $870,334 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 2 | NIH | 12/23/2024 | $819,991 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 001 | 3 | NIH | 1/14/2025 | $33,301 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 000 | 3 | NIH | 12/17/2024 | $515,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA261856 | Image Guided Cancer Therapy Training Program | 000 | 4 | NIH | 4/1/2025 | $336,199 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS132398 | Mechanisms of Epigenetic Plasticity in Neuropathic Pain | 000 | 3 | NIH | 3/10/2025 | $438,970 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA272806 | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual | 000 | 3 | NIH | 4/8/2025 | $333,632 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA289563 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor | 000 | 2 | NIH | 3/19/2025 | $81,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288515 | Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology | 000 | 2 | NIH | 4/30/2025 | $598,818 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278758 | Elucidating mechanisms underlying replication checkpoint control | 000 | 3 | NIH | 4/1/2025 | $449,475 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 000 | 2 | NIH | 11/1/2024 | $192,240 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA271223 | Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancer | 000 | 3 | NIH | 1/24/2025 | $572,302 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278940 | Role of NSD3 in regulation of cancer pathogenesis | 000 | 3 | NIH | 3/5/2025 | $580,099 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA243142 | Regulation of tumor recurrence by stress activated neutrophils | 000 | 6 | NIH | 1/28/2025 | $450,650 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA280827 | Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure. | 000 | 3 | NIH | 4/14/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 000 | 3 | NIH | 11/8/2024 | $452,669 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA287069 | A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy | 000 | 2 | NIH | 3/20/2025 | $224,100 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA272570 | Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer | 000 | 3 | NIH | 4/14/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM149226 | Regulation of Overall Cell Numbers During Epithelial Tissue Homeostasis and Pathogenesis | 001 | 3 | NIH | 3/21/2025 | $379,080 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 000 | 3 | NIH | 3/11/2025 | $634,331 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 001 | 4 | NIH | 2/13/2025 | $484,813 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB032533 | Enhanced Biomechanical Modeling of the Breast for Womens Health | 000 | 4 | NIH | 3/21/2025 | $525,446 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA263298 | Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | 000 | 4 | NIH | 3/19/2025 | $260,187 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 000 | 5 | NIH | 3/7/2025 | $414,028 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 3 | NIH | 3/7/2025 | $444,485 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 1 | NIH | 3/12/2025 | $676,584 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS117668 | Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma | 000 | 5 | NIH | 3/12/2025 | $364,500 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 3 | NIH | 2/12/2025 | $417,797 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 3 | NIH | 2/13/2025 | $444,596 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 2 | NIH | 3/18/2025 | $145,800 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 3 | NIH | 2/12/2025 | $426,474 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 2 | NIH | 2/13/2025 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236905 | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | 000 | 5 | NIH | 3/3/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 5 | NIH | 3/3/2025 | $324,064 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 000 | 4 | NIH | 3/13/2025 | $500,546 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251067 | Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2 | 000 | 5 | NIH | 3/12/2025 | $496,628 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277152 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors | 000 | 2 | NIH | 11/1/2024 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279452 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | 000 | 2 | NIH | 11/7/2024 | $604,615 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 000 | 2 | NIH | 11/22/2024 | $542,413 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 000 | 3 | NIH | 11/7/2024 | $641,069 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275990 | Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | 000 | 3 | NIH | 12/10/2024 | $529,259 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 2 | NIH | 11/7/2024 | $468,540 |
|
